Search results
30 sty 2020 · Venous thromboembolism (VTE) is rare in healthy children, but is an increasing problem in children with underlying medical conditions. Pediatric VTE encompasses a highly heterogenous population, with variation in age, thrombosis location, and underlying medical comorbidities.
- Sign In
Chętnie wyświetlilibyśmy opis, ale witryna, którą oglądasz,...
- Long-term Treatment of Venous Thromboembolism
The risk for recurrent VTE (including thrombus extension)...
- EndNote
Chętnie wyświetlilibyśmy opis, ale witryna, którą oglądasz,...
- Sign In
27 lis 2018 · The ASH guideline panel suggests using anticoagulation, rather than no anticoagulation, in pediatric patients with portal vein thrombosis (PVT) with occlusive thrombus, postliver transplant, and idiopathic PVT (conditional recommendation based on very low certainty in the evidence of effects ⊕ ).
28 lip 2020 · ASH recommends anticoagulation with occlusive thrombosis, post liver transplant, or spontaneous PVT, whereas no therapy is suggested in non-occlusive PVT or portal hypertension (2C).
1 sty 2006 · The following article describes the causes, clinical presentation and management of thrombosis in neonates, infants and older children, focusing on the clinically most relevant conditions. Topics: child, infant, thrombosis, anticoagulation, fibrinolytic agents, newborn, thrombus, thrombolytic therapy, thromboembolism.
Describe recommendations for the management of renal vein thrombosis in neonates. Describe recommendations for the management of VTE associated with central venous access devices (CVAD) in children. Describe recommendations for the management of symptomatic and asymptomatic VTE in children.
Abstract. Venous thromboembolism (VTE) in children is a rare occurrence, although in recent decades we have seen an increase due to several factors, such as the rise in survival of subjects with chronic conditions, the use of catheters, and the increased sensitivity of diagnostic tools.
In children with first VTE (CVAD and non-CVAD related), we recommend acute anticoagulant therapy with either UFH or LMWH (Grade 1B). We recommend initial treatment with UFH or LMWH for at least 5 days (Grade 1B). For ongoing therapy, we suggest LMWH or UFH.
